Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera

Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, Daniel Stadlbauer, PVI study group, Florian Krammer, Viviana Simon, Luis Martinez-Sobrido, Adolfo García-Sastre, Michael Schotsaert
doi: https://doi.org/10.1101/2021.01.26.21250543
Sonia Jangra
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chengjin Ye
3Texas Biomedical Research Institute, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raveen Rathnasinghe
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
4Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Stadlbauer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
Florian Krammer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviana Simon
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
5Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Martinez-Sobrido
3Texas Biomedical Research Institute, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adolfo García-Sastre
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
5Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai New York, NY, USA
6The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Adolfo.Garcia-Sastre@mssm.edu Michael.Schotsaert@mssm.edu
Michael Schotsaert
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Adolfo.Garcia-Sastre@mssm.edu Michael.Schotsaert@mssm.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can escape antibody-mediated protection induced by previous infection or vaccination through mutations in the spike protein. The glutamate (E) to Lysine (K) substitution at position 484 (E484K) in the receptor binding domain (RBD) of the spike protein is present in the rapidly spreading variants of concern belonging to the B.1.351 and P.1 lineages. We performed in vitro microneutralization assays with both the USA-WA1/2020 virus and a recombinant (r)SARS-CoV-2 virus that is identical to USA-WA1/2020 except for the E484K mutation introduced in the spike RBD. We selected 34 sera from study participants based on their SARS-CoV-2 spike ELISA antibody titer (negative [N=4] versus weak [N=8], moderate [N=11] or strong positive [N=11]). In addition, we included sera from five individuals who received two doses of the Pfizer SARS-CoV-2 vaccine BNT162b2. Serum neutralization efficiency was lower against the E484K rSARS-CoV-2 (vaccination samples: 3.4 fold; convalescent low IgG: 2.4 fold, moderate IgG: 4.2 fold and high IgG: 2.6 fold) compared to USA-WA1/2020. For some of the convalescent donor sera with low or moderate IgG against the SARS-CoV-2 spike, the drop in neutralization efficiency resulted in neutralization ID50 values similar to negative control samples, with low or even absence of neutralization of the E484K rSARS-CoV-2. However, human sera with high neutralization titers against the USA-WA1/2020 strain were still able to neutralize the E484K rSARS-CoV-2. Therefore, it is important to aim for the highest titers possible induced by vaccination to enhance protection against newly emerging SARS-CoV-2 variants. Two vaccine doses may be needed for induction of high antibody titers against SARS-CoV-2. Postponing the second vaccination is suggested by some public health authorities in order to provide more individuals with a primer vaccination. Our data suggests that this may leave vaccinees less protected against newly emerging variants.

Competing Interest Statement

The Garcia-Sastre Laboratory has received research support from Pfizer, Senhwa Biosciences and 7Hills Pharma. Adolfo Garcia-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Accurius and Esperovax. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Daniel Stadlbauer and Viviana Simon are also listed on the serological assay patent application as co-inventors. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.

Funding Statement

This research was partly funded by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C); by NCI grant U54CA260560; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors to A.G-S. Work on SARS-CoV-2 in the Krammer and Simon laboratories was funded by the Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. Research in Martinez-Sobrido laboratory was partially funded by the New York Influenza Center of Excellence (NYICE), a member of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract No. HHSN272201400005C (NYICE).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocols for the collection of clinical specimens from individuals with and without SARS-CoV-2 infection by the Personalized Virology Initiative were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-16-00791; IRB-20-03374). All participants provided informed consent prior to collection of specimen and clinical information. All specimens were coded prior to processing.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data will be available upon request from the corresponding authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted January 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, Daniel Stadlbauer, PVI study group, Florian Krammer, Viviana Simon, Luis Martinez-Sobrido, Adolfo García-Sastre, Michael Schotsaert
medRxiv 2021.01.26.21250543; doi: https://doi.org/10.1101/2021.01.26.21250543
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, Daniel Stadlbauer, PVI study group, Florian Krammer, Viviana Simon, Luis Martinez-Sobrido, Adolfo García-Sastre, Michael Schotsaert
medRxiv 2021.01.26.21250543; doi: https://doi.org/10.1101/2021.01.26.21250543

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3826)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)